良性前列腺增生/下尿路症状合并勃起功能障碍治疗的新靶点——PDE5  

PDE5:A new therapeutic target for lower urinary tract symptoms/benign prostatic hyperplasia combined with erectile dysfunction

作　　者：徐郑[1] 贾瑞鹏[1] XU Zheng;JIA Rui-peng(Department of Urology, Nanjing Hospital of Nanjing Medical University / Nanjing First Hospital, Nanjing, Jiangsu 210006, China)

机构地区：[1]南京医科大学附属南京医院/南京市第一医院泌尿外科,江苏南京210006

出　　处：《中华男科学杂志》2018年第4期355-359,共5页National Journal of Andrology

基　　金：江苏省青年医学人才项目(QNRC2016072);南京市医学科技发展项目(YKK16138)~~

摘　　要：伴有下尿路症状(LUTS)的良性前列腺增生(BPH)是中老年男性常见病和多发病,其发病率随着年龄的增长而显著升高。研究表明,BPH/LUTS和勃起功能障碍(ED)之间密切相关,并对中老年男性的生活质量产生重要影响。磷酸二酯酶5抑制剂(PDE5i)在治疗ED的同时,可改善患者的BPH/LUTS,PDE5有望作为BPH/LUTS合并ED治疗的新靶点。对PDE5的结构、功能以及PDE5i的作用机制进一步探索,可为BPH/LUTS合并ED的临床治疗提供更加有效的策略。Benign prostatic hyperplasia （BPH） with lower urinary tract symptoms （LUTS） is a common disease with frequent occurrence in elderly men, and its incidence shows a significant positive correlation with age. Evidence has confirmed that BPH/LUTS is closely related to erectile dysfunction （ED） and significantly affects the quality of life of elderly males. Phosphodiesterase 5 inhibi- tors （PDESi） can improve both ED and BPH/LUTS of the patients and PDE5 is expected to be a new therapeutic target for BPH/LUTS with ED. This review explores the structure and function of PDE5 and the action mechanisms of PDESi so as to provide a more effective strategy for the clinical treatment of BPH/LUTS with ED.

关 键 词：良性前列腺增生 下尿路症状 勃起功能障碍 磷酸二酯酶5 

分 类 号：R697.3[医药卫生—泌尿科学] R698[医药卫生—外科学]